Effects of Dextrose on Knee Osteoarthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03238183 |
Recruitment Status : Unknown
Verified August 2017 by Ru-Lan Hsieh, Taipei Medical University.
Recruitment status was: Not yet recruiting
First Posted : August 3, 2017
Last Update Posted : August 3, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Physical Activity Functional Disturbance | Drug: dextrose Device: hyaluronic acid | Phase 4 |
A total of 106 patients will be collected. The participants will be randomized into two groups, including hyaluronic acid group and hyaluronic acid combined dextrose group.
The hyaluronic acid group will receive 3 times of hyaluronic acid injection per week in three weeks; the hyaluronic acid combined dextrose group will receive 3 times of hyaluronic acid combined dextrose injection per week in three weeks.
The pain, physical activity, and functional performance will be evaluated.
All the evaluations will be re-evaluated at one week after injection, one month after injection, three months after injection, and six month after injection.
Subjects and the evaluator will be both blinded to the group's classification during the whole course of study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 106 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Additional Therapeutic Effects of Dextrose to Hyaluronic Acid on Knee Osteoarthritis: a Double Blind, Randomized-controlled Clinical Trial |
Estimated Study Start Date : | August 2017 |
Estimated Primary Completion Date : | July 2019 |
Estimated Study Completion Date : | July 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: hyaluronic acid combined dextrose group
Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
|
Drug: dextrose
compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
Other Name: glucose water Device: hyaluronic acid compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis |
Placebo Comparator: hyaluronic acid group
Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
|
Device: hyaluronic acid
compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis |
- physical activity-on level walking time [ Time Frame: changes from baseline to at one week after injection, one month after injection, three months after injection, and six month after injection ]10 meter walking
- physical activity-stair climbing time [ Time Frame: changes from baseline to at one week after injection, one month after injection, three months after injection, and six month after injection ]stairs climbing
- physical activity-chair rising time [ Time Frame: changes from baseline to at one week after injection, one month after injection, three months after injection, and six month after injection ]chair rising
- functional performance [ Time Frame: changes from baseline to at one week after injection, one month after injection, three months after injection, and six month after injection ]Western Ontario and McMaster Universities Osteoarthritis index
- quality of life [ Time Frame: changes from baseline to at one week after injection, one month after injection, three months after injection, and six month after injection ]Knee Injury and Osteoarthritis Outcome Score

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- knee osteoarthritis with Kellgren/Lawrence grade II or III
Exclusion Criteria:
- who have neurological deficit, such as stroke who have implant in knee

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03238183
Contact: Ru-Lan Hsieh | 228332211 | M001052@ms.skh.org.tw | |
Contact: Ru-Lan Hsieh | 228332211 | rulan@tmu.edu.tw |
Taiwan | |
Shin Kong Wu Ho-Su Memorial Hospital | |
Taipei, Taiwan, 111-01 |
Principal Investigator: | Ru-Lan Hsieh | Shin Kong Wu Ho-Su Memorial Hospital |
Responsible Party: | Ru-Lan Hsieh, Professor, Taipei Medical University |
ClinicalTrials.gov Identifier: | NCT03238183 |
Other Study ID Numbers: |
MOST 106-2314-B-341-003 |
First Posted: | August 3, 2017 Key Record Dates |
Last Update Posted: | August 3, 2017 |
Last Verified: | August 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
knee osteoarthritis hyaluronic acid dextrose therapeutic effects |
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents |